mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer

Wada,Ryuichi; Yagihashi,Soroku; Naito,Zenya

doi:10.3892/mmr.2016.5892

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer

Authors:
- Ryuichi Wada
- Soroku Yagihashi
- Zenya Naito
View Affiliations

Affiliations: Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113‑8602, Japan, Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
Published online on: October 26, 2016 https://doi.org/10.3892/mmr.2016.5892
Pages: 5104-5110
Copyright: © Wada et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Delta-human epidermal growth factor receptor 2 (HER2) is a splice variant of HER2, which lacks 16 amino acids in the extracellular domain. The aim of the present study was to elucidate the expression of delta‑HER2 and its clinicopathological correlation in Japanese patients with HER2‑overexpressing breast cancer. A total of 40 cases of HER2‑overexpressing breast cancer were investigated. The mRNA expression levels of wild type (wt)‑HER2 and delta‑HER2 were quantitated by quantitative polymerase chain reaction using RNA extracted from formalin‑fixed paraffin‑embedded specimens. In addition, the activated form of phosphorylated‑SRC (pSRC) and Ki‑67 were detected by immunostaining. The mRNA expression levels of wt‑HER2 varied largely, and the mRNA levels of delta‑HER2 were correlated with those of wt‑HER2. Furthermore, the enhanced immunostaining of pSRC was detected in 15 cases. Unsupervised hierarchal clustering of wt‑HER2, delta‑HER2 and pSRC was used to separate the cases into three clusters. In the first cluster, the levels of wt‑HER2 and delta‑HER2 were low, and pSRC immunostaining was low. Two other clusters were characterized by moderately and highly increased levels of wt‑HER2 and delta‑HER2 mRNA expression and enhanced pSRC. The delta/wt ratio was higher in the first cluster. Positive lymph node status and recurrence were more frequent in the first cluster compared with those in the two other clusters. Furthermore, the delta/wt ratio was significantly increased in lymph node‑positive and recurrent cases, compared with in lymph node‑negative and non‑recurrent cases. The present study demonstrated that delta-HER2 was expressed in Japanese patients with HER2‑overexpressing breast cancer. High mRNA expression levels of delta-HER2 were associated with pSRC and increased proliferation of tumor cells. A poor prognosis may be predicted by the increase in delta/wt ratio in HER2-overexpressing breast cancer.

View Figures

View References

1	Barnard ME, Boeke CE and Tamimi RM: Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 1856:73–85. 2015.PubMed/NCBI
2	Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
3	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
4	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
5	Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 141:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
6	Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, et al: A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol. 13:2247–2257. 1993. View Article : Google Scholar : PubMed/NCBI
7	Jackson C, Browell D, Gautrey H and Tyson-Capper A: Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int J Cell Biol. 2013:9735842013. View Article : Google Scholar : PubMed/NCBI
8	Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A and Ménard S: Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 13:221–232. 2006. View Article : Google Scholar : PubMed/NCBI
9	Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E and Jones FE: An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther. 8:2152–2162. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kwong KY and Hung MC: A novel splice variant of HER2 with increased transformation activity. Mol Carcinog. 23:62–68. 1998. View Article : Google Scholar : PubMed/NCBI
11	Siegel PM, Ryan ED, Cardiff RD and Muller WJ: Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer. EMBO J. 18:2149–2164. 1999. View Article : Google Scholar : PubMed/NCBI
12	Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D and Bentires-Alj M: Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res. 73:5320–5327. 2013. View Article : Google Scholar : PubMed/NCBI
13	Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, et al: The human splice variant Δ16HER2 induces rapid tumor onset in a reporter transgenic mouse. PLoS One. 6:e187272011. View Article : Google Scholar : PubMed/NCBI
14	Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, et al: Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. Cancer Res. 74:6248–6259. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO Classification of tumours of the breast. IARC; Lyon: 2012
16	Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
19	Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 17:461–469. 2011. View Article : Google Scholar : PubMed/NCBI
20	Natori A, Hayashi N, Soejima K, Deshpande GA, Takahashi O, Cristofanilli M, Ueno NT and Yamauchi H: A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clin Breast Cancer. 13:460–464. 2013. View Article : Google Scholar : PubMed/NCBI
21	Bianchini G and Gianni L: The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 15:e58–e68. 2014. View Article : Google Scholar : PubMed/NCBI